Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report

Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report

While standard treatment has shown efficacy in patients with breast cancer gene (BRCA) mutations, recurrence rates are high and additional effective therapies are needed. Olaparib, a poly adenosine diphosphate–ribose polymerase (PARP) inhibitor, approved for the treatment of metastatic germline BRCA...

Full description

Bibliographic Details
Main Authors: Roberta Caputo, Martina Pagliuca, Matilde Pensabene, Sara Parola, Michelino De Laurentiis
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Oncology
Subjects:
advanced breast cancer
BRCA mutation
triple negative breast cancer
PARP inhibitor
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1214660/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1214660/full

Similar Items